Company performance
Add to research
Current Price
as of Jul 11, 2025$110.27
P/E Ratio
14.87
Market Cap
$6.67B
Description
Add to research
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Metrics
Add to research
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerJAZZ
- Price$110.27-1.96%
Trading Information
- Market cap$6.67B
- Float95.49%
- Average Daily Volume (1m)667,911
- Average Daily Volume (3m)953,098
- EPS$7.82
Company
- Revenue$4.06B
- Rev growth (1yr)-0.46%
- Net income-$92.54M
- Gross margin71.15%
- EBITDA margin12.14%
- EBITDA$108.98M
- EV$10.42B
- EV/Revenue2.56
- P/E14.87
- P/S1.65
- P/B1.63
- Debt/Equity129.82
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Wikipedia